B
Brookie M. Best
Researcher at University of California, San Diego
Publications - 140
Citations - 5461
Brookie M. Best is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Population & Pregnancy. The author has an hindex of 34, co-authored 128 publications receiving 4663 citations. Previous affiliations of Brookie M. Best include Boston Children's Hospital & University of Montana.
Papers
More filters
Journal ArticleDOI
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
Scott Letendre,Jennifer Marquie-Beck,Edmund V. Capparelli,Brookie M. Best,David B. Clifford,Ann C. Collier,Benjamin B. Gelman,Justin C. McArthur,J. Allen McCutchan,Susan Morgello,David M. Simpson,Igor Grant,Ronald J. Ellis +12 more
TL;DR: Poorer penetration of ARV drugs into the CNS appears to allow continued HIV replication in the CNS as indicated by higher CSF HIV viral loads, which is probably critical in treating patients who have HIV-associated neurocognitive disorders.
Journal ArticleDOI
Resistance to intravenous immunoglobulin in children with Kawasaki disease.
Adriana H. Tremoulet,Brookie M. Best,Brookie M. Best,Sungchan Song,Susan Wang,Elena Corinaldesi,Julia R. Eichenfield,Danielle D. Martin,Jane W. Newburger,Jane C. Burns +9 more
TL;DR: An unexplained increase in IVIG-resistance was noted among patients with Kawasaki disease in San Diego County in 2006 and scoring systems based on demographic and laboratory data were insufficiently accurate to be clinically useful in an ethnically diverse population.
Journal ArticleDOI
Recognition of a Kawasaki Disease Shock Syndrome
John T. Kanegaye,Matthew S. Wilder,Delaram Molkara,Jeffrey R. Frazer,Joan M. Pancheri,Adriana H. Tremoulet,Virginia E. Watson,Brookie M. Best,Jane C. Burns +8 more
TL;DR: Kawasaki disease shock syndrome is associated with more-severe laboratory markers of inflammation and greater risk of coronary artery abnormalities, mitral regurgitation, and prolonged myocardial dysfunction and may be resistant to immunoglobulin therapy and require additional antiinflammatory treatment.
Journal ArticleDOI
Greater Tenofovir-Associated Renal Function Decline with Protease Inhibitor-Based versus Nonnucleoside Reverse-Transcriptase Inhibitor-Based Therapy
Miguel Goicoechea,Shanshan Liu,Brookie M. Best,Shelly Sun,Sonia Jain,Carol A. Kemper,Mallory D. Witt,Catherine Diamond,Richard Haubrich,Stan G. Louie +9 more
TL;DR: Treatment with TDF and PI/r was associated with greater declines in renal function over 48 weeks compared with T DF+NNRTI-based regimens, and tenofovir plasma concentration was not associated with CrCl over time.
Journal ArticleDOI
Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki Disease
Jane C. Burns,Brookie M. Best,Asuncion Mejias,Lynn Mahony,David E Fixler,Hasan S. Jafri,Marian E. Melish,Mary Anne Jackson,Basim I. Asmar,David J. Lang,James D. Connor,Edmund V. Capparelli,Monica L. Keen,Khalid Mamun,Gregory F. Keenan,Octavio Ramilo +15 more
TL;DR: Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment.